.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Baxter
Boehringer Ingelheim
Cantor Fitzgerald
Citi
Federal Trade Commission
Merck
Daiichi Sankyo
Novartis

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,859,504

« Back to Dashboard

Which drugs does patent 8,859,504 protect, and when does it expire?


Patent 8,859,504 protects NINLARO and is included in one NDA.

This patent has ninety-four patent family members in thirty-five countries.

Summary for Patent: 8,859,504

Title:Boronate ester compounds and pharmaceutical compositions thereof
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Elliott; Eric L. (Watertown, MA), Ferdous; Abu J. (Nottingham, MD), Kaufman; Michael J. (Lexington, MA), Komar Lay; Sonja A. (Belmont, MA), Mazaik; Debra L. (Holliston, MA), McCubbin; Quentin J. (Belmont, MA), Nguyen; Phuong M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Skwierczynski; Raymond D. (Andover, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Newton, MA), Zawaneh; Peter N. (Brookline, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/667,164
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
Millennium PharmsNINLAROixazomib citrateCAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,859,504

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,018,301► Subscribe
9,175,018Boronate ester compounds and pharmaceutical compositions thereof► Subscribe
9,175,017Boronate ester compounds and pharmaceutical compositions thereof► Subscribe
2,015,307,523► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,859,504

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Philippines12015501192► Subscribe
Philippines12015501191► Subscribe
Peru10782014► Subscribe
Peru10762014► Subscribe
Peru10652014► Subscribe
Peru10642014► Subscribe
Peru02562010► Subscribe
New Zealand624123► Subscribe
New Zealand624122► Subscribe
New Zealand624121► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Cipla
Covington
McKesson
Farmers Insurance
Boehringer Ingelheim
Cerilliant
Fuji
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot